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Abstract 
When blood contacts the surface of a material, sev-
eral processes take place including the activation of co-
agulation and immune systems. The aim of this work is 
to study in vitro the biological reactions seen from the 
point of view ofhemocompatibility and cytocompatibility 
of a new polymer suggested as an artificial surface for 
cardiovascular applications: CarbofiJm® coated poly-
etherimide (C®PEI) in comparison to polyetherimide 
(PEl) , the uncoated form. PEl and C®PEI showed no 
signs of acute cytotoxicity although following long term 
incubation with PEl cytotoxicity was somewhat in-
creased; both materials supported good endothelial cell 
adhesion with a higher level of cell proliferation on the 
coated form. No significant difference was detected in 
the activation of the inflammatory response and in 
thrombogenicity tested by assay of prostaglandin E2 
(PGE2) and tromboxane B2 (TXB2) respectively, fol-
lowing incubation of the biomaterials with platelet-rich 
plasma (PRP). Complement activation assessed by sodi-
um dodecy! sulfate - polyacrylamide gel electrophoresis 
(SDS-PAGE)/Westem Blot analysis of both contacting 
plasma and protein which adsorbed on the surface of the 
polymers showed both materials to be activators of com-
plement. In conclusion, Carbofilm® coating, showing 
lower cytotoxic activity and higher endothelial cell 
growth in comparison with uncoated material , seems to 
increase PEl compatibility. 
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Introduction 
The use of synthetic materillls for biomedical de-
vices has increased considerably in"reeent years with the 
availability of new polymers having appropriate mechan-
ical and physical properties for specific clinical applica-
tions (Remes and Williams, 1992).' These applications 
depend on the complexity of biological reactions 'that 
occur at the interface between tissues and· implant 
(Peluso et al., 1994). To date, no synthetic material 
developed is entirely passive to blood. When blood 
contacts the surface of a material, several processes such 
as the activation of both coagulation and iriunune sys-
tems take place in order to protect the host agaiiist ~ not­
self' components (Woffmdin and Hoenich, 1988}. •Sev-
eral humoral and cellular factors are recruited by a com-
plex mechanism resulting· in the reeognition of foreign 
surfaces by the host (Montdargent et al., 1992). Among 
these, the activation of the complement system is an 
important event resulting in the production of proteolytic 
fragments which are then recognized by different leuko-
cyte subsets through specific receptors thus initia:ting the 
cell-mediated inflammatory response (Kaz.atchkine and 
Carreno, 1988; Labarre et al., 1993). Platelet adhesion 
and secretion of intracellular components· constitUte 
another consequence of the contact of blood with foreign 
material surface (Kottke-Marchant et al. , 1989). More-
over platelets catalyze the interactions among plasma 
coagulation proteins, leading to thrombin formation 
(Leake et al., 1989). 
One of the most promising approaches to reducing 
the thrombogenicity of the blood contacting surface of 
synthetic polymers is to coat the surface with endothelial 
cells (ECs). Attempts were made either by seeding the 
polymer surface with low numbers of ECs at surgery 
and allowing gradual growth to confluence in vivo 
(Ortenwall et al., 1988) or by sodding at high densities 
to produce a cell coated: graft at implantation (Jarrell et 
al., 1986). ' ''\J, 
It is generally accepted; that the physicochemical 
composition of the substrate is a key determinant in the 
amount and confqrmation of adsorbed cell adhesion pro-
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teins which mediate cell adhesion (Ratner, 1993). Be-
sides fibronectin and extracellular matrix coating, pyro-
lytic carbon is widely used in prosthetic devices that 
come into contact with blood (Pacagnella et al., 1986). 
Since pyrolytic carbon is one of the best artificial mate-
rials currently available in terms of chemical inertness 
and absence of thrombogenic reactions (Aebischer et al., 
1988), the aim of this work is to study, in vitro, the bio-
logical reactions, seen from the point of view of hemo-
compatibility and cytocompatibility of a new polymer 
proposed for cardiovascular application, that is, Carbo-
film® coated Polyetherimide (C®PEI) in comparison with 
the uncoated form. 
Materials and Methods 
Biomaterials 
Polyetherimide (C38H250 6N2,)n (PEl, Litrex I; 
Petrochemie Danubia GmbH, Mannsworth, Austria) is 
a thermoplastic amorphous polymer with a glass transi-
tion temperature of about 217 °C. The poly-(etherimide) 
resin is the latest synthesized polyimide (General Elec-
tric Co., Mt. Vernon, IN) and probably represents the 
most successful combination of polyimide performance 
and processability. This polymer is synthesized by reac-
tion of dianhydrides containing ether links and diamines; 
the polyetherimide is characterized by high strength, 
rigidity and dimensional stability and good electrical 
insulation properties, which are largely maintained after 
prolonged exposure to temperatures up to about 180°C. 
This polymer is resistant to a wide range of solvents 
including alcohols and fully halogenated compounds. 
Carbofi]m® coated Polyetherimide (C®PEI, furnish-
ed by Tecnobiomedica, Rome, Italy) is made of the 
same material, PEl, modified by a pyrolytic carbon coat-
ing obtained by a physical vapor deposition (PVD) proc-
ess, similar to that employed for valve prostheses. This 
technique is performed in a high vacuum and the trans-
fer is obtained by bombarding the target with an ion 
beam at 40-200°C range (Pacagnella et al., 1986). 
Medical grade Silicone (Perthese® LP 502-1, Labo-
ratoire Perouse Implant, Borne!, France) and glass 
(microscope slide glass) were used as controls for hemo-
compatibility and cytocompatibility assessment. 
All samples were squares of 1 em x 0.5 em, provid-
ed with siliconized edges to avoid direct contact of the 
material with the medium. The sterilization procedures 
were performed according to manufacturers' specifica-
tions: after three washes of 30 minutes each in distilled 
water and in 0.9% (volume/volume, v/v) NaCl solution, 
the materials were autoclaved at 121 °C for 20 minutes. 
Cytotoxicity evaluation 
An in vitro screening test on cell cultures was car-
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ried out, to evaluate the acute cytotoxicity of the chemi-
cals that could be released by the test materials into the 
culture medium. Evaluation was performed by neutral 
red vital stain (1 hour of exposure) uptake test {Ameri-
can Society for Test.ing of Materials (ASTM), 1985} and 
also by lactate dehydrogenase (LDH) concentration test 
on a monolayer of murine fibroblasts 3T3 (ATCC CRL 
1658; American Type Culture Collection, Rockville, 
MD) cultured in Dulbecco's modified Eagle's medium 
(DMEM, Sigma, St. Louis, MO) supplemented with 
10% (v/v) fetal bovine serum (FBS, Sigma), penicillin 
(100 U ml- 1), streptomycin (100 g rnl- 1) and 0.03% 
(v/v) L-glutamine. LDH is an enzyme released from the 
cell when the cell membrane is ruptured so the amount 
of LDH present in the media at the completion of the 
test correlates with the amount of cell death in the cul-
ture. In a 24-well plate, 1. 3 x 104 cells/ cm2 were added 
onto the surface of PEl and C®PEI in triplicate; two ad-
ditional cultures were used as negative controls and two 
others were treated with Triton X-100 providing positive 
controls for LDH analysis. After a 96 hour incubation, 
LDH activity (Sigma Kit) was measured at 340 nm, cor-
responding to the oxidation of NADH to NAD+ in the 
presence of LDH and pyruvate. 
To mimic the long-term effects of the body environ-
ment on the biomaterials, extracts were prepared in 
phosphate-buffered saline (PBS) , corresponding to a sur-
face area of 1 cm2/rnl, at 60°C for 10 days (artificial 
ageing extract) according to ASTM (1985) guidelines. 
The extracts were tested by the microculture tetrazolium 
assay using 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyl-
tetrazolium bromide (MTT assay). The assay is based 
on the observation that viable cells are able to metabo-
lize a water-soluble tetrazolium dye 3-(4,5-dimethylthia-
zol-2-yl)-2-5-diphenyltetrazolium bromide (MTT), into 
an insoluble forrnazan salt product by the action of mito-
chondrial succinate dehydrogenase (Kirkpatrick and 
Dekker, 1992; Smith et al., 1992; Dekker et al., 1994). 
The extracts, obtained by maintaining the samples 
for 10 days at 60°C, were diluted with growth medium, 
containing double concentrated serum, to a ratio of 1:4. 
The dilution was added to the cell cultures; medium 
obtained in the same way without addition of polymers, 
provided the negative control, while 2% (v/v) dimethyl-
sulfoxide (DMSO) in growth medium was used as posi-
tive control because of its inhibitory action on cell 
viability (Ignatius and Claes, 1995). 
NIH 3T3 cells (8 x 1o3/well) were plated into 96 
well microtitre plates; after 6 hours plating, the growth 
medium was replaced by 200 J.d/well of diluted extracts. 
At least six replicates were prepared for each material 
and for positive and negative controls. The cells were 
exposed to the extracts for 4, 24, 48 hours at 37°C in a 
5% C02 atmosphere. Then, 10 J.!l per well of an MTT 
Evaluation of carbofilm-coated polyetherimide 
solution (5 mg.ml-1 PBS) were added and the plate was 
incubated for 4 hours. The medium was removed and 
the formazan crystals dissolved in dimethylsulfoxide 
(DMSO). The colorimetric staining was then evaluated 
on a multiwell plate reader (450 Microplate Reader, 
BioRad, Richmond, CA) at 540 nm. 
Adhesion and proliferation test 
Endothelial cells were obtained by isolation from 
human umbilical cord vein (HUVEC), collected from 
Caesarean deliveries according to the method described 
by Jaffe et al. (1973). Cells were cultured in tissue-cul-
ture grade polystyrene plates (Corning, Cambridge, MA) 
precoated with a 0.5% (v/v) gelatin (Sigma) solution in 
complete medium composed of M199 (Sigma) supple-
mented with 20% (v/v) FBS (Sigma), heparin (50 U/ml 
Sigma), 300 ;.tg/ml endothelial cell growth supplement, 
produced according to Maciag et al. (1979), 0.03% 
(v/v) L-glutamine (Gibco, Paisley, UK), 100 U/ml peni-
cillin and 100 ;.tglml streptomycin (Sigma) . Cells used 
for the experiments were between 2nd and 5th passage 
after the confluency of the culture. 
Human umbilical vein endothelial cells were identi-
fied by immunofluorescent staining for von Willebrand 
factor (DAKO, Glostrup, Denmark) . Briefly, after fix-
ing with 3% (v/v) paraformaldehyde, endothelial cells 
were rinsed with phosphate buffered saline (PBS), per-
meabilized with 0.1% (v/v) Triton X-100 (1 minute) 
rinsed with PBS, incubated with primary antibody and 
stained with fluorescent goat anti-rabbit IgG. Negative 
controls were human fibroblasts (MRC5 cell line) and 
HUVEC not coated with primary antibody. 
HUVEC were placed on the biomaterial surface at 
5 x 1oJ cells/cm2 in a 24 microplate well. Adhesion 
and proliferation tests were performed after 6 hours and 
5 days, respectively. The materials, after rinsing in 
PBS, were fixed 2b minutes at 60°C and stained with a 
0.025% (weight/volume, w/v) Acridine Orange solution, 
a nucleic acid staining dye (Kepner and Pratt, 1994). 
Cell number on each material was performed using a 
fluorescence microscope (Aristoplan; Leitz, Milano, 
Italy) and results are expressed as percent cell number 
with respect to plated cells (5 x 1o3 cells/cm2), 
considered as 100%. 
Hemocompatibility evaluation 
Platelet rich plasma (PRP) was prepared using 
pooled venous blood from healthy donors collected in 
siliconized tubes containing 3.5% (w/v) sodium citrate 
as anticoagulant. PRP was obtained by centrifugation at 
500 x g for 10 minutes at 4 °C. Before using, it was 
analyzed using a flow cytofluorimeter (Becton Dickin-
son, Meylan, France) to evaluate the cellular population. 
PRP ( 1. 8 ml) was added to each well of a 24-well 
microtitre plate (Coming) containing squares of 1 em x 
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0.5 em of PEl, C®PEI, silicone and glass as negative 
and positive control respectively (n = 16) . The plate 
was then rotated for 30 minutes at room temperature for 
the contact between PRP and biomaterials. After the 
contact period, a platelet activity inhibiting solution, 
made of ethylene diarninotetracetic acid (EDT A) and in-
domethacin, was added to PRP specimens in the ratio of 
10 parts of PRP and 1 part of solution. The PRP speci-
mens were purified by solid/liquid extraction using 
Amprep minicolumns (Amersham International pic , 
Amersham, UK) before assaying arachidonic acid 
products. The concentrations of Prostaglandin E2 
(PGE2) and Tromboxane B2 (TXB2) were determined 
with enzyme immunoassay (EIA) using PGE2 EIA Kit 
(Cayman Chemical Company, Ann Arbor , MI) and 
TXB2 EIA system (Amersham) respectively. Results 
are expressed as pg/rnl . 
Complement activation was studied through the 
analysis of complement components bound on the sur-
face. A sample of PRP was inactivated by heating at 
60°C for 30 minutes and used as additional control to-
gether with a sample of PRP inactivated with EDT A. 
Squares of biomaterials were incubated with plasma for 
1 hour at room temperature. After removal of plasma, 
squares were washed four times in PBS. The squares 
were then transferred into Eppendorf tubes and incu-
bated at 90°C for 10 minutes in a 2% (w/v) sodium do-
decyl sulfate (SDS). Samples were analyzed by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) accord-
ing to the method of Laemrnli (1970) and the gel was 
stained with a Silver Stain kit (BioRad). Western blot 
was performed using polyclonal anti-C3 antibody 
(DAKO) followed by horseradish peroxidase conjugated 
antibody. ECL Western blotting detection reagents 
(Amersham) were used for revelation. 
Statistical analysis 
Statistical analysis of the data was carried out using 
a PC-compatible equipped with SPSS for Windows soft-
ware. Bonferroni evaluation was performed to compare 
cytotoxicity, adhesion and proliferation results ; p value 
was obtained from the analysis of variance (ANOV A) 
table. The conventional 0.05 level was considered to 
reflect statistical significance. 
Results 
Cytotoxicity evaluation 
Fibroblasts in contact with PEI and C®PEI showed 
no sign of damage such as morphological elongation, 
loss of neutral red, pycnotic nuclei , etc. . In contrast , 
cells cultured in contact with Triton X-100 (positive con-
trol) were scanty, rounded and had lost the vital stain 
(results not shown). These results were confirmed by 
Materials 
PEl 
Carbofilm PEl 
Positive Control** 
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Table 1. MTI test expressed as negative control (in % )*. 
4 hours 
68.66 ± 6.97 
68.45 ± 5.48 
46.74 ± 3.11 
24 hours 
73 .78 ± 9.16 
70.43 ± 6.71 
37 .39 ± 2.16 
48 hours 
43.12 ± 3.22 
52.37 ± 13.07 
23.55 ± 1.42 
Relative MTT formazan formation by NIH 3T3 cells after incubation with extracts of the materials studied for 4 , 24, 
48 hours. The formazan formation is expressed as a percentage of the amount produced by cells incubated with fresh 
culture medium (means ± standard deviation of six replicates) . Dilution factors of the primary extract = 4X. 
* Negative control: Cells without polymer extracts in the culture medium. 
** Positive control: Cells with 2% DMSO in the growth medium. 
Table 2. Cytocompatibility results. 
Carbofilm PEl PEl Silicone Glass 
Cell Growth* (%) 453 . 14 ± 84.00 386.37 ± 70.00 121.80 ± 40.60 219.42 ± 83.00 
Adhesion**(%) 77 .37 ± 13 .70 70.15 ± 10.90 54.28 ± 5.00 75.24 ± 12.00 
* Day 5 cell count/plating cell density xlOO. 
** Cell count at 6 hours incubation/plating cell density xlOO. 
The materials with cells on the luminal surface were stained with Acridine Orange solution and cells were quantified 
using a fluorescent microscope. n = 4; values are mean ± standard deviation. 
PEl = polyetherirnide; CarbofilmPEI = Carbofilm coated polyetherimide. 
Table 3. Arachidonic acid metabolism. 
Carbofilm PEl PEl Silicone Glass 
PGE2 (pg/ml) 58 .94 ± 8.20 56.08 ± 6.70 51.25 ± 9.20 67.70 ± 6.40 
TXB2 (pg/ml) 290.75 ± 111.50 209 .10 ± 53 .50 242.50 ± 49.30 299.30 ± 124.50 
Arachidonic acid metabolites enzyme immunoassay results at 30 minutes contact between platelet rich plasma and 
biomaterials. 
n = 16; values are mean ± standard deviation. 
LDH release assessment (Fig. 1) as a method for the 
evaluation of the cell membrane integrity . 
MTI test results are expressed in Table 1 where the 
absorbance results showed the percentage of cell growth 
in relation to the negative control. Formazan salt pro-
duction was significantly different between cells treated 
with DMSO (positive control) and both test materials at 
each incubation time. Both materials revealed a de-
crease in formazan salt production measured at 48 hours 
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Results are expressed as pg/ml . 
incubation in comparison with 4 and 24 hour incubation 
periods. This decrease was significant only for PEl 
(Bonferroni test with a = 0.05). 
Cytocom pati bili ty 
All surfaces showed great endothelial cell attach-
ment with a significantly lower cell adhesion on silicone 
than on the other materials tested; no significant differ-
ences in adhesion were noted between PEl, C®PEI and 
Evaluation of carbofilm-coated polyetherimide 
300 
a 250 
2200 
~ 
..... 
. _g; 150 
~ § 100 
50 
lmCarbofilmPEI 
CJCELLS CJCELLS + Triton XIOO 
Figure 1. Results provided by assessment of cell mem-
brane damage, are expressed as LDH activity (U/1) ± 
standard deviation at 340 nm. 
glass although C®PEI supported the highest number of 
adherent cells (Bonferroni test with significance level 
0.05). There was significantly more cell growth on PEl 
and C®PEI (p < 0.05) than on glass (positive control) 
or silicone; among all samples, C®PEl showed the 
greatest cell growth (Table 2). 
Hemocompatibility 
Arachidonic acid metaboli te results are shown in Ta-
ble 3. No significant differences in TXB2 concentration 
were observed among materials and values decreased as 
follows: glass, C®PEI, silicone, and PEL PGE2 levels 
were higher in plasma which had contacted glass and no 
difference was revealed between the other materials. 
The SDS-PAGE electrophoresis of proteins present 
on the surface of biomaterials, incubated with platelet 
rich plasma, is presented in Figure 2a. The predominant 
protein on all surfaces had molecular weight from 29 to 
51 KDa. The surface of C®PEI appeared to have the 
least adsorbed protein. 
The immunoblot, incubated with polyclonal anti-C3 
antibody, showed C3 fragments both on the surface of 
every biomaterial and in the plasma after contact with 
the materials (Fig. 2b). The predominant polypeptides 
had molecular weights of - 70 KDa, and - 40 KDa, 
representing the /3-chain of C3/C3b and fragments of 
iC3b respectively. These two bands )lave been found in 
the control PRP, in the incubation plasma used for the 
complement activation test and, at higher concentration, 
bound on the surface of the four materials. In Figure 
2b, bands near 200 KDa, 120 KDa and 29 KDa were 
visible only for the biomaterials eluted proteins (lanes 2 , 
3, 4, and 5) and represented C3, a-chain of C3/C3b, 
and fragments of C3c, respectively. Generally, we have 
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Figure 2. (a) . SDS-PAGE patterns of protein layers 
adhered to biomaterials, after in vitro incubation with 
platelet rich plasma (PRP): (1) CarbofilmPEl, (2) PEl, 
(3) Glass , ( 4) Silicone, (5) Molecular Weight, (6) 
Control (PRP) . (b). lmmunoblot of C3 fragments 
present on the surface of biomaterials incubated with 
PRP. Lane 1: control PRP; Lane 2: CarbofilmPEl; 
Lane 3: PEl; Lane 4: Silicone; Lane 5: Glass; Lane 6: 
PRP after contact with CarbofilmPEl; Lane 7: PRP after 
contact with PEl; Lane 8: PRP after contact with 
silicone; Lane 9: PRP after contact with glass. 
observed a reduced intensity band at 29 KDa and 75 
KDa for silicone, and at 120 KDa and 70 KDa for glass 
compared to the other materials. 
Discussion 
To date, no synthetic material developed is entirely 
passive to blood. In particular, polymer surfaces devel-
oped for cardiovascular application cause platelet adhe-
sion, followed by platelet release and aggregation. In 
addition, polymers are also able to stimulate coagulation, 
complement activation and leukocyte adhesion (Kottke-
Marchant et al., 1989). 
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Endothelial cells play a key role in the development 
and dissolution of thrombi, producing factors such as 
urokinase-type plasminogen activator, tissue type plas-
minogen activator, plasminogen activator inhibitor-!, 
platelet activating factor, prostacyclin, and nitric oxide 
(Vanhoutte, 1989). Attempts to form a complete endo-
thelial cell layer on synthetic graft surfaces of small-
diameter vascular prostheses have been made in order to 
overcome the thrombogenic properties of the exposed 
surface (Zhang et al. , 1995; Burmeister et al., 1996; 
Poole-Warren et al., 1996). With this in mind, the abil-
ity of endothelial cells to form a monolayer and to pro-
liferate on a material, that was to be used for cardio-
vascular application, became an important and interest-
ing parameter to study together with blood compatibility 
tests. 
The aim of this work was to evaluate, in vitro, the 
biocompatibility of a new material , C'8PEI in compari-
son with PEL Cytotoxicity screening showed that both 
materials exerted no acute toxic effect on cultured fibro-
blasts as all the cultures showed a morphological appear-
ance and LDH levels similar to that of negative control. 
The MTI test (demonstrating not only membrane integ-
rity, but also intracellular mitochondrial succinate dehy-
drogenase activity) revealed a decrease in formazan pro-
duction, an index of a toxic effect, for both the materials 
after a longer incubation period and this was particularly 
evident for PEL 
As complement activation plays an important role in 
the activation of leukocytes (Labarre et al., 1993), the 
complement-activation induced by the materials has to be 
evaluated as part of its biocompatibility. Since deposi-
tion of C3b is believed to be the initiating event for effi-
cient complement activation, a surface that does not bind 
C3b is expected to be a poor activator (Cheung et al., 
1990; Lin et al., 1992). C3 deposition at the surface 
and C3 assay to detect the degree of complement activa-
tion in serum, that had been in contact with the surface 
of the materials, revealed that all the biomaterials were 
activators of complement. We can hypothesize that the 
large accumulation of C3 on the surface (200 KDa in the 
immunoblotting) was due to complement activation and 
not to spontaneous adsorption of C3, because, both the 
EDT A control involving heat-inactivated plasma were 
negative. The different immunoblot pattern of comple-
ment C3 fragment adsorbed on the tested surfaces in 
comparison with the one obtained from control plasma 
allows us to confirm a complement activation, this is 
also supported by the observation of fragments of iC3b 
at 40 KDa from the conversion of C3b at 70 KDa pre-
sent at higher concentration bound to the surface rather 
than in plasma analyzed. PGE2 and TXB2 concentra-
tions, markers of inflammatory phenomenon and platelet 
aggregation, evidenced no significant difference in the 
122 
four materials considered: the higher result was for the 
positive control material , glass, and the lower value for 
the negative control material , silicone, while PEl and 
C'8PEI were quite similar for PGE2 and TXB2 levels. 
C®PEI induced a TXB2 production not significantly 
higher than the values induced by PEl, indicating only 
a slightly higher activity on platelet aggregation. 
In conclusion, on the basis of our results, neither 
material gave any sign of acute cytotoxicity and, at" long 
term incubation, PEl was less biocompatible exhibiting 
lower cell vitality. No significant difference was detect-
ed in the activation of the inflammatory response or in 
complement activation. In addition the ability of endo-
thelial cells to form a monolayer and to proliferate on 
both the materials was shown to be good and C®PEI 
showed higher endothelial cell growth, a sign of better 
endothelialization. Therefore, Carbofilm® coating of 
PEl seems to increase material biocompatibility when 
compared to uncoated PEl that itself is an excellent bio-
compatible material (Peluso et al. , 1994). The improve-
ment of cytocompatibility and hemocompatibility of the 
coated material, however, needs more experiments to 
relate the obtained results, for example, to dynamic tests 
which approach in vivo conditions. 
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Discussion with Reviewers 
G. Laroche: It is not clear in my mind that the tech-
nique that is described as being used to coat the polyi-
mide surface is PVD. Indeed, physical vapor deposition 
consists in vaporizing a coating substance on a substrate 
under vacuum. Most of the time, the coating media is 
heated, therefore, allowing its deposition onto the sur-
face. However, coatings deposited in such a manner 
give rise to poor adhesion as the vaporized species do 
not have enough energy to be efficiently anchored onto 
the surface. To my point of view, the technique that is 
described by the authors (bombardment of a target with 
an ion beam) actually refers to sputtering deposition. 
This latter technique allows a better adhesion between 
the coating and the substrate as the coating molecules 
reach the surface with more energy. 
Authors: We confirm that the technique used to coat 
the polyetherimide surface is a PVD process involving 
mass transfer from a pyrolytic carbon target to the 
substrates under high vacuum. The CarbofiJm® adhesion 
properties, turbostratic structure and impurity content 
M. Bosetti et al. 
have been reported by Paccagnella et al . (1986). 
S.J. Northup: Based on the physical properties ofPEI, 
this material is more likely to be considered as a substi-
tute for pyrolytic carbon in heart valves or other soft tis-
sue applications that require a rigid material (e.g., injec-
tion ports). Why was pyrolytic carbon excluded from 
the experiment? 
Authors: In this work, we have studied if pyrolytic car-
bon coating lead to an increased hemocompatibility and 
cytocompatibility of PEI with the aim of obtaining a 
material with the physical properties of PEI and the 
biocompatibility properties of pyrolytic carbon. So we 
have studied pyrolytic carbon as PEI coating. 
S.J. Northup: If silicone was one of the samples to be 
evaluated, why was the blood collected in siliconized test 
tubes? 
Authors: Silicone was used as negative control for 
PGE2 and TXB2 because it was described in the litera-
ture as a non-activating material on the arachidonic acid 
cascade; so, to avoid contact of blood with glass or 
polypropylene when preparing PRP, we preferred to use 
siliconized test tubes. 
S.J. Northup: Are there any qualitative or quantitative 
analytical data on the chemical residues in the extract 
evaluated in the MIT assay? Is the amount and identity 
of residual chemicals in an extract prepared at 60°C 
comparable to that found in an extract prepared at 37 °C? 
Authors: We have not done a qualitative or quantitative 
analytical study on the chemical residues in the material 
extracts evaluated in the MIT assay. ASTM (1985) 
Guidelines were followed to study long-term effects of 
the body environments on biomaterials cytotoxicity. 
A. Dekker: The general conclusion of the MIT test is 
that cells in contact with extracts of the biomaterials 
tested formed less formazan salts than the cells incubated 
with fresh culture medium. In contrast, endothelial cells 
grew well on the biomaterials, without signs of cytotox-
icity. This contrast is not surprising, since the osmolali-
ty of the diluted extracts is likely to be too high. Name-
ly, the extracts of the biomaterials in PBS were diluted 
1:4 with double concentrated culture medium, which 
contains twice the physiological salt concentration. PBS 
contains a physiological salt concentration. Therefore, 
the diluted extract will possess a salt concentration that 
is considerably higher than the physiological one. Such 
high osmolalities will impede cell growth. The usage of 
normal concentrated culture medium for dilution of the 
extracts would solve this problem. Please comment. 
S.J. Northup : It is remarkable that an extract of PEI 
and C™PEI disrupted mitochondrial metabolism, yet 
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the materials had no effect on lysosomal integrity 
(neutral red assay) or membrane integrity (LDH) assay), 
and supported enhanced cell proliferation. Please 
comment. 
Authors: There is a misunderstanding regarding the 
methods to prepare material extracts for MTT assay : 
only serum is double-concentrated in the medium for 
dilution of the extracts. MTT results on biomaterial 
extracts should not be compared to neutral red, LDH 
and cell proliferation studies. MIT gives us information 
about long-term cytotoxicity, while the other methods 
evaluate acute cytotoxicity (neutral red and LDH) and 
cytocompatibility (proliferation). 
A.Dekker: Essentially, in this study the biocompatibili-
ty of two quite different materials was tested, polyetheri-
rnide and pyrolytic carbon, respectively. The latter one 
was coated on polyetherimide. Is the biological per-
formance of the carbon coated on polyetherimide, as you 
tested it, comparable with that of pyrolytic carbon coated 
on other materials, as described by other authors? How 
much does the substrate for the carbon coating influence 
the biocompatibility of the carbon surface? 
Authors: Pyrolytic carbon was used in coating of dif-
ferent types of implant prostheses such as dental im-
plants, percutaneous devicP-s, tendon and tracheal re-
placements and, particularly, heart valve prostheses. 
Recently , it has been used as coating for vascular pros-
theses in Teflon® and Dacron® (Sbarbati et al., 1991 ; 
Cenni et al., 1995). In these studies, pyrolytic carbon 
coating shows a lower thrombogenicity and enhances in 
vitro endothelial cell attachment and growth when 
compared with uncoated materials. 
S.J. Northup: Please comment on the risk of adverse 
health effects from circulating activated complement and 
activated complement that is bound to a material. 
Authors: Complement activation has many clinical 
consequences on adverse health effects that correlate 
with production and release of inflammatory mediators, 
e .g. , leukopenia and hypoxia associated with 
hemodialysis (Woffindin and Hoenich, 1988) and lung 
injury after cardiopulmonary bypass (Gillinov et al., 
1993). 
The immobilized C3 on polymer surface can, most 
probably, function as receptors, e.g., neutrophils, poten-
tially producing a local reaction, chemotaxis, increased 
vascular permeability, and vasodilatation. We believe 
that the absence of detectable C3 deposition on the 
surface does not exclude active complement products 
formed in the fluid in contact with the surface (Liu and 
Elwing, 1994) so that both the fluid phase activation and 
C3b binding to an activating surface are studied to 
evaluate biomaterial complement activation. 
Evaluation of carbofilm-coated polyetherimide 
L.A. Culp: Regarding Figure 2b, how do the authors 
know that the respective bands on their gels can be 
defmitively identified as C3 and C3 fragments? Another 
disturbing point about Figure 2b is the relative under-
loading of protein in Janes 6-9 compared to Janes 2-5; 
perhaps C3 and its fragments do appear in lanes 6-9 but 
the authors have not loaded a comparable amount of 
total protein. 
W. van Oeveren: The Results on immunoblot (Fig. 
2b) are not clear. Is Figure 2b only presenting proteins 
bound to the biomaterial surface, or is lane 6-9 present-
ing the C3 fragments in serum? An important conclu-
sion from these qualitative complement tests could be 
that despite reduced protein binding to carbofilm, com-
plement binding and activation is high, indicating poor 
biocompatibility to this aspect. 
Authors: We have identified C3 and C3 fragments 
bands in the blot incubated with anti-C3 antibodies based 
on molecular weights (Berger et al., 1994). In Figure 
2b we have loaded the same amount of total protein in 
Janes 2-9. Lanes 6-9 present C3 fragments in platelet 
rich plasma, used as a control at a higher total protein 
concentration than in lane 1; lanes 2-5 present C3 
fragments eluted from the materials. The proposed 
conclusion on our qualitative complement tests IS 
interesting but needs more tests to be confirmed. 
L.A. Culp: The authors should state whether their 
cultured 3T3 cells contained serum (type of serum?) in 
the medium when tested with biomaterials. This is 
critical to evaluate whether cell surface proteins are 
interacting with the material directly or indirectly via 
adsorbed serum proteins. The same comment applies to 
culture of the endothelial cells in Materials and 
Methods. 
G. Laroche: Experiments on platelet and fibrinogen ad-
hesion would have brought additional useful information 
on carbon-coated polyetherimide performances. 
Authors: Our medium used to culture 3T3 and 
HUVEC cells on biomaterials contained fetal bovine 
serum (Sigma). In this study, we have not evaluated if 
cell interaction with the material is mediated by adsorbed 
serum proteins. We have only evaluated differences in 
cell adhesion and proliferation between coated and un-
coated material. Biomedical carbon surfaces and their 
interactions with plasma proteins have been studied by 
Feng and Andrade (1994a,b, 1995). 
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